Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 10-12B Registration of securities
- 3.1 EX-3.1
- 3.2 EX-3.2
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 10.28 EX-10.28
- 21.1 EX-21.1
- 23.1 EX-23.1
MRTX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated May 8, 2013 (except Note 21, as to which the date is June , 2013), in the Registration Statement (Form 10) of Mirati Therapeutics, Inc. for the registration of its common stock.
| Ernst & Young LLP |
Montreal, Canada
The foregoing consent is in the form that will be signed upon the completion of the Arrangement as described in Note 21 to the consolidated financial statements.
Montreal, Canada | /s/ Ernst & Young LLP(1) |
May 10, 2013 |
|
(1)CPA auditor, CA, public accountancy permit no. A120254